Navigation Links
Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
Date:2/5/2009

on (57.4%), asthenia (51.8%) and nausea (50%). Only two patients went off study due to "dermatitis".

About Myocet(TM) (Nonpegylated Liposomal Doxorubicin)

Myocet is a liposome-encapsulated doxorubicin-citrate complex. By encapsulating doxorubicin in a liposome - a manufactured, microscopic, vesicle consisting of discreet aqueous compartments surrounded by membranes composed of naturally occurring fats - its distribution in the body is altered in such a way as to reduce doxorubicin's toxicity. Extensive clinical studies of Myocet in women with breast cancer have shown that the cardiac toxicity of doxorubicin can be significantly reduced, while the efficacy of the drug is maintained. This delivery system does not encompass pegylation and yields very little hand foot syndrome.

The results of the SOLTI study further support an ongoing registration trial in patients with metastatic HER-2-overexpressing breast cancer, sponsored by Sopherion Therapeutics, LLC. This is a pivotal Phase III trial of Myocet(TM), paclitaxel and trastuzumab vs. paclitaxel and trastuzumab that uses progression-free survival as the primary efficacy endpoint, with careful monitoring for cardiac safety.

About Sopherion Therapeutics, LLC

Sopherion Therapeutics, LLC, is a privately-held biotechnology company based in Princeton, New Jersey. The Company is focused on developing novel anti-cancer therapies for patients suffering with advanced cancer, particularly metastatic disease. Sopherion is dedicated to the acquisition, discovery, development and commercialization of novel anti-cancer therapies with unique therapeutic activities that address unmet medical needs in and extend human life. In 2004, Sopherion entered into an exclusive licensing agreement with Zeneus Pharma Ltd. (now Cephalon, Inc.) for the future commercialization of Myocet in North America. For more information, visit

SOURCE Sopherion Therapeutics, LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) to Present at 11th Annual BIO CEO & Investor Conference
2. Cell Therapeutics, Inc. Provides Update on the Special Meeting of Shareholders
3. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
4. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
5. Cell Therapeutics, Inc. (CTI) Zevalin Joint Venture Conference Call to be Webcast with Slides
6. Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
7. Cell Therapeutics, Inc. (CTI) to Report 2008 Third Quarter Financial Results on November 7
8. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
9. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
10. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $24.7 Million of Senior Convertible Notes
11. Cell Therapeutics, Inc. (CTI) to Present at Three Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... (PRWEB) February 26, 2015 Regis Technologies ... the development of oncology drug substances. , Regis Technologies ... of their new Potent Compound Suite (PCS) for 2015. ... 36,000 square foot, cGMP facility in Morton Grove, Illinois. ... manufacturing of potent compounds up to about one kilogram ...
(Date:2/26/2015)... (NASDAQ: ONCE ) announced today that members ... and Company Health Care Conference on Wednesday, March 4, ... Copley Place. To access the live webcast ... please visit the "Upcoming Events" section within the "News ... www.sparktx.com .  A replay of the webcast will ...
(Date:2/25/2015)... 25, 2015 /CNW/ - Radient Technologies Inc. (TSX-V: RTI) (the ... results for the third quarter of its fiscal year ... Discussion and Analysis, and the CEO & CFO certifications ... 31, 2014 are available on www.SEDAR.com ... The Corporation is also pleased to announce the appointment ...
(Date:2/25/2015)... Salt Lake City, Utah (PRWEB) February 25, 2015 ... was recently awarded a $604,000 grant from ... Science, Technology, Engineering, and Mathematics (STEM) program. , ... students demonstrating a financial need, enabling them to ... or bachelor’s degree in a STEM discipline. Institutions ...
Breaking Biology Technology:Regis Extends cGMP Services to Oncology Market 2Spark Therapeutics to Participate in the 35th Annual Cowen and Company Health Care Conference 2Radient Technologies Inc. Releases Third Quarter Results and Appoints New Interim CFO 2SLCC Receives $600K National Science Foundation Grant 2
... 12 Bayer CropScience announced,today that its vegetable ... Paragon Seed Inc. Based in Salinas, California, Paragon ... lettuce varieties. The,company with sales of US-Dollar 8.5 ... market leaders in the United States in this ...
... RAMON, Calif., Dec. 12 Odyssey Thera, Inc.,announced ... Office granted,U.S. Patent No. 7,306,914, entitled "Protein-fragment Complementation,Assays ... ADME, cancer,biology, immunology, infectious disease and gene therapy." ... PCA process., The patent describes a method ...
... N.M., Dec. 12 Biomoda, Inc. (OTC,Bulletin Board: ... New,Mexico Institute of Mining and Technology (New Mexico ... to collaborate on clinical,studies and the development of ... commercialization of its assay for the early,detection of ...
Cached Biology Technology:Bayer CropScience's Vegetable Seed Business Nunhems Acquires US Lettuce Seed Company Paragon Seed 2Bayer CropScience's Vegetable Seed Business Nunhems Acquires US Lettuce Seed Company Paragon Seed 3Odyssey Thera Granted U.S. Patent for Animal Imaging 2Biomoda Announces Collaborative Agreement With New Mexico Tech 2
(Date:2/24/2015)... , Feb. 24, 2015 Research and ... the addition of the "Global 2D Gesture ... The analysts forecast the Global ... CAGR of 32.12% over the period 2014-2019 ... in non-traditional sectors is one of the major ...
(Date:2/12/2015)... 12, 2015   MedNet Solutions , a ... study management systems, has recently bolstered its ... iMedNet as the eClinical ... and healthcare consultants.  Building on the Program,s existing ... and numerous co-marketing opportunities), MedNet,s new and improved ...
(Date:2/5/2015)... , 5. Februar 2015 Marken ... Logistikunternehmen und hat eine neue Marketingkampagne gestartet, ... (Clinical Logistics Organization – CLO) der Branche ... lautet First , mit Schwerpunkt auf ... http://photos.prnewswire.com/prnh/20150205/173753 Logo - ...
Breaking Biology News(10 mins):Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3
... advantage of improvements in satellite sensor capabilities offer the ... East Asian forest fires, urban exhaust, and industrial production ... China, the worlds most populated country, has experienced rapid ... considerable expansion in automobile use over the last two ...
... YORK (MARCH 17, 2008) Take a deers body, attach a ... a saiga the odd-ball antelope with the enormous schnoz that ... are as endangered as they are strange-looking due to over-hunting. ... routes are in jeopardy as well. ...
... decade that a protein associated with the HIV virus is ... it worked. A multidisciplinary team from the University of Illinois ... design of therapeutic agents that cross a variety of membrane ... in Angewandte Chemie. The TAT protein transduction domain of ...
Cached Biology News:NASA satellite measures pollution from east Asia to North America 2NASA satellite measures pollution from east Asia to North America 3Asia's odd-ball antelope faces migration crisis 2Researchers discover how stealthy HIV protein gets into cells 2Researchers discover how stealthy HIV protein gets into cells 3
... Xcell microbial system, 100 to 240 ... electroporation of bacterial and fungal cells. ... PC module for exponential decay delivery, ... (5 each of 0.1 and 0.2 ...
... solution. In PBS containing ... other proprietary stabilizers; 0.2 ... to stabilize activity of ... at high conjugate dilutions ...
... The Gene Pulser Xcell eukaryotic ... 50-60 Hz, is used for ... system includes the main unit, ... microfarad range) or square-wave pulses, ...
... MacMelt software is used on ... melting profile of any DNA sequence ... in optimizing placement of primers and ... denaturing gradient gel electrophoresis (DGGE), constant ...
Biology Products: